Aphakia Market Research Report- Forecast till 2030

Aphakia Market Information: By Types (Primary, Secondary), Causes (Congenital Aphakia, Surgical Aphakia, Acquired Aphakia), Treatment (Spectacles, Contact Lenses, Intraocular Lens Implantation), End Users- Forecast Till 2030

ID: MRFR/MED/2963-HCR | February 2023 | Region: Global | 85 Pages         

Aphakia Market Speak to Analyst Request a Free Sample

Aphakia Market ScenarioThe Aphakia Market is expected to reach USD 3,876.9 Million by 2030 at 11.2% CAGR during the forecast period 2022-2030. Aphakia describes the absence or dislocation of the crystalline eye lens. It is the most commonly occurs due to the presence of diseases such as trauma and congenital conditions or after surgery for cataract removal. Increasing prevalence of diseases such as diabetes & trauma and increasing number of accident have boosted the market growth of the aphakia. According to World Health Organization (WHO), in 2014, 285 million people were visually impaired across the globe in which 246 million had low vision and 39 million were completely blind. Additionally, According to the WHO, 422 million people have diabetes and this number is increasing at the rate of 8.5%. Moreover, increasing geriatric population, rapidly developing healthcare sector, and increasing demand for the better treatment of the ophthalmic diseases fuel the market growth. On the other hand, the high cost of the surgery and limited availability of the treatment may slow the market growth.


Intended Audience



  • Pharmaceutical and Biotechnological Companies

  • Research and Development (R&D) Companies

  • Ophthalmic Companies

  • Hospitals and Clinics

  • Academic Institutes and Universities


Figure 1: Aphakia Market, by Causes Share, 2016 (%) Aphakia Market

Sources: WHO, annual reports, press release, white paper, company presentation


Segmentations


The aphakia market has been segmented on the basis of types, causes, treatment, and end user.


On the basis of type, the aphakia market is segmented into primary, and secondary.


On the basis of cause, the aphakia market is categorized into congenital aphakia, surgical aphakia, acquired aphakia, and others. Acquired aphakia is further segmented into traumatic extrusion, posterior dislocation, couching, and other.


On the basis of treatment, the aphakia market is segmented into spectacles, contact lenses, intraocular lens implantation, refractive surgery, and others. The spectacles are sub-segmented into +10D, +3-4D, and other. Refractive surgery is further segmented into keratophakia, epikeratophakia, and hyperopic LASIK.


On the basis of end user, the aphakia market is segmented into hospitals, ophthalmic clinics, and others.


Regional AnalysisThe Americas dominates the aphakia market owing to the increasing prevalence of people with aphakia. It was estimated that 6.1 million (5.1%) of Americans have pseudophakia/aphakia. Additionally, well-developed technology, huge diabetic population, and strong government support for research & development will fuel the market growth.


Europe is the second leading market across the globe, which is followed by Asia Pacific. Availability of funds for research, huge geriatric population and government support for research & development will drive the market.


Asia Pacific is the fastest growing aphakia market due to the presence of rapidly growing economy, huge patient pool, increasing prevalence of ophthalmic diseases, and presence of huge geriatric population.


On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited availability of medical facilities, and poor political conditions in Africa.


Key PlayersSome of key the players in the aphakia market are Johnson & Johnson Services, Inc. (US), Ophtec BV (Netherland), Alcon Laboratories, Inc. (Switzerland‎), Bausch & Lomb (US), Carl Zeiss AG (Germany), Rayner Company (US), Bohus BioTech AB (Sweden), CooperVision, Inc. (US), Lifecore Biomedical, LLC (US), Aetna Inc. (US), Ciba Vision (Switzerland), and Menicon (Singapore).


Research Methodology Global Aphakia Market


Sources: WHO, annual reports, press release, white paper, and company presentation


 



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 3,876.9 Million
  CAGR   11.2%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types, Causes, Treatment, and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Johnson & Johnson Services, Inc. (US), Ophtec BV (Netherland), Alcon Laboratories, Inc. (Switzerland‚Äé), Bausch & Lomb (US), Carl Zeiss AG (Germany), Rayner Company (US), Bohus BioTech AB (Sweden), CooperVision, Inc. (US), Lifecore Biomedical, LLC (US), Aetna Inc. (US), Ciba Vision (Switzerland), and Menicon (Singapore)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing geriatric population
  • Rapidly developing healthcare sector
  • Increasing demand for the better treatment of the ophthalmic diseases


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Aphakia market is projected to grow at a 11.2% CAGR between 2022-2030.

    The Americas is expected to dominate theaphakia market.

    Ophthalmic clinics, hospitals, and others are the major end users of aphakia market.

    Developing healthcare sector and rising geriatric population are the key factors driving the aphakia market growth.

    Limited availability of treatment and high surgery cost are factors that may limit the aphakia market growth.